M&T Bank Corp Boosts Stake in Edwards Lifesciences Corporation $EW

M&T Bank Corp grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 20.9% during the fourth quarter, HoldingsChannel reports. The firm owned 35,754 shares of the medical research company’s stock after buying an additional 6,182 shares during the period. M&T Bank Corp’s holdings in Edwards Lifesciences were worth $3,048,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of EW. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth about $25,000. Hantz Financial Services Inc. lifted its stake in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares in the last quarter. Dorato Capital Management acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $29,000. Rakuten Securities Inc. lifted its stake in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in shares of Edwards Lifesciences during the third quarter worth about $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president owned 21,266 shares in the company, valued at $1,782,941.44. The trade was a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 88,096 shares of company stock worth $7,288,799. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on EW shares. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. UBS Group restated a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, Evercore restated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Trading Down 0.5%

NYSE:EW opened at $82.75 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The business’s 50-day simple moving average is $82.16 and its 200 day simple moving average is $82.74. The stock has a market cap of $47.71 billion, a price-to-earnings ratio of 44.01, a price-to-earnings-growth ratio of 2.09 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the previous year, the firm posted $0.64 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.